Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 18, 2026 08:00 ET | Source: Tenvie Therapeutics, Inc.

Tenvie Therapeutics Appoints Don O’Sullivan, Ph.D., MBA, as Chief Business Officer

Tenvie Therapeutics appoints Dr. Don O'Sullivan as Chief Business Officer to lead strategic collaborations as the company advances toward the clinic
February 18, 2026 07:00 ET | Source: EyePoint, Inc.

EyePoint Appoints Michael Campbell as Chief Commercial Officer

– Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma –– Brings established track record of successful product launches and oversight of...
February 17, 2026 15:24 ET | Source: Spherix Global Insights

Gazyva Establishes Early Clinical Credibility in Lupus Nephritis Three Months Post-Approval, According to Spherix Global Insights

Exton, PA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- – Three months into its U.S. launch for lupus nephritis (LN), Roche/Genentech’s Gazyva (obinutuzumab) is entering a treatment landscape shaped not only...
February 17, 2026 07:01 ET | Source: African Diaspora Network

Bridging Continents and Capital: How ADIS26 Connects Africa’s Innovators with Silicon Valley

Santa Clara, California, Feb. 17, 2026 (GLOBE NEWSWIRE) -- At a defining moment for Africa’s economic and innovation landscape, the African Diaspora Network (ADN) will once again bring the world’s...
February 17, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Change to the Roche Enlarged Corporate Executive Committee

Basel, 17 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the appointment of Mark Dawson, M.D., Ph.D., as the new Head of Roche Pharma Research and Early Development (pRED),...
February 16, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease

MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years Up to 30% of people with membranous nephropathy progress to...
February 12, 2026 16:05 ET | Source: Celcuity Inc.

Celcuity Appoints Charles Romp to its Board of Directors

MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the...
February 12, 2026 10:57 ET | Source: NMDP

NMDP Appoints Ginna Laport, MD, to New Senior Physician Leadership Role

NMDP recently hired Ginna Laport, M.D., as senior vice president, strategic, scientific and clinical partnerships.
February 12, 2026 08:05 ET | Source: CRB Group, Inc.

CRB Appoints John R. Lupa, Jr. as Vice President, National Construction

Kansas City, Mo., Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRB announced today that John R. Lupa, Jr. has joined the firm as Vice President, National Construction. An engineering, construction and...
February 09, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight

New york, USA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight ...